Background Heart failure with left ventricular (LV) hypertrophy is often associated with
insulin resistance and inflammation. Recent studies have shown that dipeptidyl peptidase 4 …

Elevated free fatty acids (FFAs) are a risk factor for type 2 diabetes. Endothelial dysfunction
induced by high levels of FFAs is one of the mechanisms related to the progression of …

Progression of diabetes mellitus is accompanied by metabolic disorders together with
psychological deficits including cognitive dysfunctions. Herein, we used a murine …

Aims The enzyme dipeptidyl peptidase-4 (DPP-4) is a key player in the degradation of
incretin hormones that are involved in glucose metabolism. DPP-4 is also expressed on …

Aims: To assess the long‐term safety and the sustained glycaemic control of vildagliptin
compared with rosiglitazone over 2‐year treatment in drug‐naïve type 2 diabetes mellitus …

Vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor is effective in reducing HbA1c levels
in patients with type 2 diabetes (T2DM) when administered as monotherapy, dual or triple …

The role of dipeptidyl peptidase-IV (DPP4) as both a regulatory enzyme and a signalling
factor has been evaluated and described in many studies. DPP4 inhibition results in …

Aim: To assess the safety of vildagliptin versus all comparators (ACs) with regard to organs,
systems or tissues of particular interest in type 2 diabetes (T2DM) and areas of potential …

Objective: To determine the effect of Vildagliptin in non-alcoholic, fatty liver disease patients
with dyslipidemia. Methods: A randomized placebo controlled trial was conducted at …